Renalytix PLC
LSE:RENX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Renalytix PLC
LSE:RENX
|
UK |
|
Seoul City Gas Co Ltd
KRX:017390
|
KR |
|
MCAN Mortgage Corp
TSX:MKP
|
CA |
|
Tachikawa Corp
TSE:7989
|
JP |
|
D
|
Dreambed Co Ltd
TSE:7791
|
JP |
|
H
|
Halmek Holdings Co Ltd
TSE:7119
|
JP |
Renalytix PLC
Renalytix Plc manufactures medical devices and equipment. The company is headquartered in Penarth, South Glamorgan. The company went IPO on 2018-11-06. The firm is focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care. The firm's diagnostic platform, KidneyIntelX, is designed to scale across kidney disease conditions beyond diabetic kidney disease. The firm is evaluating a range of new indications in chronic kidney disease, cardio-renal disease, chronic kidney disease in diverse populations and coronavirus disease (COVID)-related kidney disease. KidneyIntelX platform facilitates the identification and promotes the effective management of patients at risk of early-stage diabetic kidney disease (DKD), progression by combining diverse data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record (HER) using a proprietary algorithm to generate a unique patient risk score.
Renalytix Plc manufactures medical devices and equipment. The company is headquartered in Penarth, South Glamorgan. The company went IPO on 2018-11-06. The firm is focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care. The firm's diagnostic platform, KidneyIntelX, is designed to scale across kidney disease conditions beyond diabetic kidney disease. The firm is evaluating a range of new indications in chronic kidney disease, cardio-renal disease, chronic kidney disease in diverse populations and coronavirus disease (COVID)-related kidney disease. KidneyIntelX platform facilitates the identification and promotes the effective management of patients at risk of early-stage diabetic kidney disease (DKD), progression by combining diverse data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record (HER) using a proprietary algorithm to generate a unique patient risk score.
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.
